Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Lyle Tron Gomez

Neurology Portland, OR Medical Doctor

NPI 1316389273 CMS profile 6278541

9135 Sw Barnes Rd Ste 461, Portland, OR 97225

Open in the dashboard

General payments

$2,595

133 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Lyle Tron Gomez of Portland, OR is reported in the CMS Open Payments database as having received $2,595 across 133 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $299 6
2023 General $26 1
2022 General $864 47
2021 General $1,098 63
2020 General $248 15
2019 General $61 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Lyle Tron Gomez
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to John Lyle Tron Gomez were reported at $299. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year John Lyle Tron Gomez Neurology median Middle half National median
2019 $61 $474 $118–$2,177 $163
2020 $248 $367 $82–$2,309 $114
2021 $1,098 $438 $104–$2,547 $132
2022 $864 $442 $103–$2,388 $149
2023 $26 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $299 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Horizon Therapeutics plc $519 30 payments
  2. AbbVie, Inc. $430 16 payments
  3. SK Life Science, Inc. $205 13 payments
  4. Teva Pharmaceuticals USA, Inc. $174 10 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $148 6 payments
  6. UCB, Inc. $139 6 payments
  7. Biogen, Inc. $132 6 payments
  8. Genzyme Corporation $110 6 payments
  9. Supernus Pharmaceuticals, Inc. $106 5 payments
  10. Amgen Inc. $94 5 payments
  11. Other $538 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,583 132 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. UPLIZNA $519 30 payments
  2. UBRELVY $252 11 payments
  3. NURTEC ODT $203 10 payments
  4. Vimpat $139 6 payments
  5. BOTOX $139 2 payments
  6. QULIPTA $134 2 payments
  7. AJOVY $118 7 payments
  8. TROKENDI XR $106 5 payments
  9. AUBAGIO $89 5 payments
  10. ADUHELM $76 3 payments
  11. Other $572 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,165

Median for Neurology: 833

Drug cost

$100,123

Median for Neurology: $202,670

Branded share of claims

21.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 20 $36,092
Aimovig Autoinjector Erenumab-Aooe Brand 31 $24,993
Qulipta Atogepant Brand 15 $18,016
Carbidopa-Levodopa Carbidopa/Levodopa Brand 122 $3,234
Gabapentin Generic 146 $2,357
Pregabalin Generic 142 $2,130
Oxcarbazepine Generic 24 $1,542
Propranolol Hcl Generic 89 $1,438
Duloxetine Hcl Generic 68 $1,338
Primidone Generic 49 $1,289

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$51,646

Medicare's payments for the services billed

Medicare patients

272

Average age 73

Services billed

698

175 women, 97 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 53%
Depression 37%
Chronic kidney disease 27%
Diabetes 25%
Osteoporosis 23%
Ischemic heart disease 22%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

133 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record